ELUT (Elutia) Net Loan

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ELUT Elutia Inc ELUT
34 GF Score
Price $0.96
GF Value $0.90
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Elutia Net Loan?

Net Loan only applies to banks and insurance companies.

ELUT
34GF Score
Elutia Inc ELUT
Net Loan is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Elutia (ELUT) Overvalued in 2026?

Based on GuruFocus' analysis, Elutia stock appears to be overvalued. The current stock price of $0.96 is trading 6.7% above its estimated GF Value™ of $0.90. GuruFocus considers Elutia to be Fairly Valued.

Key valuation signals for ELUT:

  • Net Loan:
  • GF Value™: $0.90 vs. price of $0.96 (6.7% above fair value)
  • GF Score™: 34/100 with 5 warning signs

No single metric tells the full story. See the ELUT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Elutia Business Description

Address 20 Firstfield Road, Gaithersburg, MD, USA, 20878
Elutia Inc develops proprietary drug-eluting biomatrix products for use in surgical reconstruction and related applications. These products are designed to improve the interaction between implanted medical devices and patients. Its products include CanGaroo, designed for implantable electronic devices, and SimpliDerm, used in soft tissue repair, with functions related to implant support and wound management. The company operates in two segments: Women's Health and Cardiovascular. The majority of revenue is derived from the Women's Health segment.
34GF Score

Get the complete analysis for ELUT

Net Loan is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.96
Price
$0.90
GF Value